Rutger H.T. Koornstra
A5004262252- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- vaccines and immunoinformatics approaches
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Bladder and Urothelial Cancer Treatments
- Colorectal Cancer Treatments and Studies
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Computational Drug Discovery Methods
- Economic and Financial Impacts of Cancer
- Cancer, Hypoxia, and Metabolism
- Cancer survivorship and care
- Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Ocular Oncology and Treatments
- Pharmacogenetics and Drug Metabolism
- Gene expression and cancer classification
- Nonmelanoma Skin Cancer Studies
Radboud University Nijmegen
2015-2024
Radboud University Medical Center
2015-2024
Rijnstate Hospital
2018-2024
Princess Máxima Center
2021
Royal North Shore Hospital
2021
Ospedale Papa Giovanni XXIII
2021
The Netherlands Cancer Institute
2009-2021
Princess Alexandra Hospital
2021
Melanoma Institute Australia
2021
University Medical Center
2014-2021
The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial evaluate as adjuvant therapy in resected, high-risk stage III melanoma.Patients completely resected melanoma were randomly assigned (with stratification according cancer geographic region) receive 200 mg of (514 patients) or placebo (505 intravenously every weeks for total 18 doses (approximately...
Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown.To investigate the association between irAEs and recurrence-free survival (RFS) double-blind EORTC 1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy placebo for treatment of high-risk stage III melanoma.A total 1019 adults melanoma were randomly assigned on a 1:1 ratio to receive or placebo. Eligible 18 years older complete resection...
We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage melanoma. On basis 351 recurrence-free survival (RFS) events at a 1.25-year median follow-up, prolonged RFS (hazard ratio [HR], 0.57; P < .0001) compared placebo. This led approval adjuvant treatment by Medicines Agency US Food Drug Administration. Here, we report an updated...
Thus far, dendritic cell (DC)-based immunotherapy of cancer was primarily based on in vitro-generated monocyte-derived DCs, which require extensive vitro manipulation. Here, we report a clinical study exploiting primary CD1c(+) myeloid naturally circulating the blood.Fourteen stage IV melanoma patients, without previous systemic treatment for metastatic disease, received autologous activated by only brief (16 hours) ex vivo culture and loaded with tumor-associated antigens tyrosinase...
Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical in cancer patients. In this phase III trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant nDCs ( n = 99) or placebo 49). Active consisted of intranodally injected autologous CD1c+ conventional plasmacytoid DCs loaded tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas secondary endpoints...
Introduction: Immune checkpoint inhibitors have taken an important place in the treatment of different types malignancies. These drugs are known to specific immune-mediated adverse events. We describe a case severe nephrotic syndrome secondary with nivolumab patient renal cell carcinoma. Case Presentation: A 62-year-old man was treated for papillary carcinoma type 2 8 weeks when he admitted hospital and acute kidney injury. Renal biopsy showed focal segmental glomerulosclerosis. Treatment...
Abstract Background Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect be counteracted by immunosuppressive mechanisms. Cisplatin has shown immunomodulatory effects in vivo which may enhance efficacy of DC vaccination. Methods This is a prospective, randomized, open-label phase 2 study (NCT02285413) including stage III and IV melanoma patients receiving 3 biweekly vaccinations gp100 tyrosinase mRNA-loaded monocyte-derived DCs with or without...
β-adrenergic receptors are upregulated in melanoma cells and contribute to an immunosuppressive, pro-tumorigenic microenvironment. This study investigated the prognostic predictive value of β-adrenoreceptor blockade by β-blockers EORTC1325/KEYNOTE-054 randomised controlled trial.Patients with resected stage IIIA, IIIB or IIIC regional lymphadenectomy received 200 mg adjuvant pembrolizumab (n = 514) placebo 505) every three weeks for one year until recurrence unacceptable toxicity. At a...
Abstract Introduction Inhibitors of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target rapamycin (PI3K/AKT/mTOR) pathway can overcome endocrine resistance in estrogen receptor (ER) α-positive breast cancer, but companion diagnostics indicating PI3K/AKT/mTOR activation and consequently are lacking. PIK3CA mutations frequently occur ERα-positive cancer result vitro . Nevertheless, prognostic treatment-predictive value these is contradictive. We tested clinical validity other...
Abstract Background The Estrogen Receptor alpha (ERα) is the key transcriptional regulator in luminal breast cancer and therefore main target for adjuvant treatment of this subtype. Luminal gene signatures are dictated by capacities ERα, which a direct consequence receptors binding preference at specific sites on chromatin. identification ERα genome-wide level has greatly enhanced our understanding biology cell lines tumours, but technique its limitations with respect to applicability...
Abstract Introduction Activation of the phosphatidylinositol-3-kinase (PI3K) and/or mitogen-activated protein kinase (MAPK) pathways results in anti-estrogen resistance vitro , but a biomarker with clinical validity to predict intrinsic has not been identified. In metastatic breast cancer patients previous exposure endocrine therapy, addition mammalian target rapamycine (mTOR) inhibitor shown be beneficial. Whether or on adjuvant treatment might benefit from these drugs is currently unclear....
To the Editor,Uveal melanoma (UM) is a rare type of melanoma, with an incidence 4.4 cases per million in Europe each year [1]. During recent years, different treatment approaches have been teste...
The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes highly elevated serum lactate dehydrogenase (LDH) remain very poor. aim this study was to explore whether normalized LDH after targeted therapy could benefit from subsequent treatment immune checkpoint inhibitors (ICI). Data all BRAF-mutant metastatic a at baseline (≥2× upper limit normal) receiving first-line between 2012 and 2019 in Netherlands were collected. Patients stratified...